Study record
Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination
Yin Y, Li Y, Ma B et al. · Adv Sci (Weinh) · 2024
Human obs.SeveralEvidence tier BAlso: Cell study (in vitro)Also: Animal study (in vivo)
What this study reported
Measured lower MOTS-c in serum and tumour tissue from patients with ovarian cancer, with lower levels associated with poorer prognosis. In ovarian cancer cells and tumour-bearing mice, exogenous MOTS-c was associated with less proliferation, migration and invasion, with cell cycle arrest and apoptosis, and with LARS1 degradation through competition with USP7.
Limitations
Patient sample sizes are not reported and the clinical association is correlative; animal work uses implanted tumours; the mechanism rests on a single interaction partner.
Study record
| Study model | Human observational |
|---|---|
| Substance studied | SeveralMore than one of these is central to the paper (common for reviews). |
| Species | human, mouse |
| System studied | Serum and tumour MOTS-c from patients with ovarian cancer, ovarian cancer cell lines and mouse tumour models |
| Population | patients with ovarian cancer and comparison subjects |
| Design | Patient-sample biomarker study with cell and animal experiments |
| Sample size as reported | Not reported |
| Control group | comparison samples without ovarian cancer; untreated cells and mice |
| Route (data field only) | Not reported |
| Endpoints measured | serum and tumour MOTS-c; patient prognosis; cell proliferation, migration and invasion; cell cycle arrest and apoptosis; LARS1 ubiquitination; tumour growth in mice |
| Pathways measured | Apoptosis · Other |
| Research areas | Cancer |
| Evidence tier | B — Other human study |
| Publication types | Journal Article, Research Support, Non-U.S. Gov't |
Appraisal
Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.
- Relevance to MOTS-c
- Direct
- Model applicability
- Human
- Sample size
- Not reported
- Controls
- Appropriate
- Outcome validity
- Surrogate
- Support for its own conclusion
- Moderate
Provenance
- Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
- Annotated from the published abstract.
- Editorial review: approved (2026-11-11).
- Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.